Unlike current first-line therapies such as RAS or SGLT2 inhibitors that primarily modulate hemodynamics and show limited efficacy in advanced chronic kidney disease [51], HKL directly targets core pathological mechanisms including mitochondrial dysfunction and inflammatory activation. Here, SLC5A2 is linked to chronic kidney disease.